The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Advice for community hematologists when prescribing bispecific antibodies for multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares advice for community hematologists when prescribing bispecific antibodies for multiple myeloma (MM). These antibodies have specific and unique toxicities, notably cytokine release syndrome (CRS), which requires timely intervention and step-up dosing to mitigate severe risk. Cytopenia and infections should also be managed. Talquetamab is unique because it has a low infection risk but can cause on-target, off-tumor effects, which tend to fade over time. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
